Heerma van Voss, M R
Vesuna, F http://orcid.org/0000-0002-0356-5096
Bol, G M
Afzal, J
Tantravedi, S
Bergman, Y
Kammers, K
Lehar, M
Malek, R
Ballew, M
ter Hoeve, N
Abou, D
Thorek, D
Berlinicke, C
Yazdankhah, M
Sinha, D
Le, A
Abrahams, R
Tran, P T
van Diest, P J
Raman, V
Article History
Received: 11 October 2016
Revised: 16 June 2017
Accepted: 13 July 2017
First Online: 4 September 2017
Competing interests
: VR and PTT have received a patent for the use of RK-33 as a radiosensitizer (US 8,518,901). VR, GMB and PJvD have received a patent for the use of DDX3 as a cancer biomarker (US 9,322,831). PJvD, PTT and VR are on the advisory board of Natsar Pharmaceuticals.